Search Keyword:


Search option:


IID00391
UniprotQ96RI1
ProteinBile acid receptor
GeneNR1H4
OrganismHomo sapiens
Sequence LLPS PhaSepDB
PhaSePro
LLPSDB
DrLLPS
Network xml rdf
Structure
Experiment
  :order   disorder   conflict   PDB cluster   ProS   Pfam Domain   SEG
486
 order/disorder by at least rule
     disorder by at least rule
     order by at least rule
 order/disorder by majority rule
Seq 249-486 Hetero tetramer : IID00083Complex
 Evidence X-RAY 3bej A Reference
       Region 3bej A 249-258 disorder
       Region 3bej A 259-353 order
       Region 3bej A 354-356 disorder
       Region 3bej A 357-485 order
       Region 3bej A 486-486 disorder
 Evidence X-RAY 3bej B Reference
       Region 3bej B 249-257 disorder
       Region 3bej B 258-485 order
       Region 3bej B 486-486 disorder
Seq 252-486 Hetero dimer : IID00083Complex
 Evidence X-RAY 3dct A Reference
       Region 3dct A 252-257 disorder
       Region 3dct A 258-486 order
 Evidence X-RAY 3dcu A Reference
       Region 3dcu A 252-257 disorder
       Region 3dcu A 258-486 order
 Evidence X-RAY 3fxv A Reference
       Region 3fxv A 258-352 order
       Region 3fxv A 353-357 disorder
       Region 3fxv A 358-470 order
       Region 3fxv A 471-472 disorder
       Region 3fxv A 473-485 order
       Region 3fxv A 486-486 disorder
 Evidence X-RAY 3hc5 A Reference
       Region 3hc5 A 257-257 disorder
       Region 3hc5 A 258-486 order
 Evidence X-RAY 3hc6 A Reference
       Region 3hc6 A 257-486 order
 Evidence X-RAY 3okh A Reference
       Region 3okh A 258-409 order
       Region 3okh A 410-410 disorder
       Region 3okh A 411-485 order
       Region 3okh A 486-486 disorder
 Evidence X-RAY 3oki A Reference
       Region 3oki A 258-486 order
 Evidence X-RAY 3oki C Reference
       Region 3oki C 258-486 order
 Evidence X-RAY 3olf A Reference
       Region 3olf A 258-486 order
 Evidence X-RAY 3olf C Reference
       Region 3olf C 258-486 order
 Evidence X-RAY 3omk A Reference
       Region 3omk A 258-486 order
 Evidence X-RAY 3omk C Reference
       Region 3omk C 258-486 order
 Evidence X-RAY 3omm A Reference
       Region 3omm A 258-486 order
 Evidence X-RAY 3omm C Reference
       Region 3omm C 258-486 order
 Evidence X-RAY 3oof A Reference
       Region 3oof A 258-486 order
 Evidence X-RAY 3oof C Reference
       Region 3oof C 258-486 order
 Evidence X-RAY 3ook A Reference
       Region 3ook A 258-486 order
 Evidence X-RAY 3ook C Reference
       Region 3ook C 258-486 order
 Evidence X-RAY 3p88 A Reference
       Region 3p88 A 258-486 order
 Evidence X-RAY 3p89 A Reference
       Region 3p89 A 258-260 disorder
       Region 3p89 A 261-411 order
       Region 3p89 A 412-413 disorder
       Region 3p89 A 414-485 order
       Region 3p89 A 486-486 disorder
 Evidence X-RAY 3rut A Reference
       Region 3rut A 258-486 order
 Evidence X-RAY 3ruu A Reference
       Region 3ruu A 258-486 order
 Evidence X-RAY 3rvf A Reference
       Region 3rvf A 257-258 disorder
       Region 3rvf A 259-486 order
 Evidence X-RAY 5q0j A Reference
       Region 5q0j A 258-486 order
 Evidence X-RAY 5q0j C Reference
       Region 5q0j C 258-486 order
 Evidence X-RAY 5q0k A Reference
       Region 5q0k A 258-469 order
       Region 5q0k A 470-473 disorder
       Region 5q0k A 474-484 order
       Region 5q0k A 485-486 disorder
 Evidence X-RAY 5q0l A Reference
       Region 5q0l A 258-486 order
 Evidence X-RAY 5q0l C Reference
       Region 5q0l C 258-485 order
       Region 5q0l C 486-486 disorder
 Evidence X-RAY 5q0m A Reference
       Region 5q0m A 258-468 order
       Region 5q0m A 469-473 disorder
       Region 5q0m A 474-484 order
       Region 5q0m A 485-486 disorder
 Evidence X-RAY 5q0n A Reference
       Region 5q0n A 258-485 order
       Region 5q0n A 486-486 disorder
 Evidence X-RAY 5q0n C Reference
       Region 5q0n C 258-484 order
       Region 5q0n C 485-486 disorder
 Evidence X-RAY 5q0o A Reference
       Region 5q0o A 258-486 order
 Evidence X-RAY 5q0o C Reference
       Region 5q0o C 258-485 order
       Region 5q0o C 486-486 disorder
 Evidence X-RAY 5q0p A Reference
       Region 5q0p A 258-486 order
 Evidence X-RAY 5q0p C Reference
       Region 5q0p C 258-486 order
 Evidence X-RAY 5q0q A Reference
       Region 5q0q A 258-467 order
       Region 5q0q A 468-474 disorder
       Region 5q0q A 475-484 order
       Region 5q0q A 485-486 disorder
 Evidence X-RAY 5q0q C Reference
       Region 5q0q C 258-467 order
       Region 5q0q C 468-472 disorder
       Region 5q0q C 473-484 order
       Region 5q0q C 485-486 disorder
 Evidence X-RAY 5q0r A Reference
       Region 5q0r A 258-468 order
       Region 5q0r A 469-472 disorder
       Region 5q0r A 473-484 order
       Region 5q0r A 485-486 disorder
 Evidence X-RAY 5q0s A Reference
       Region 5q0s A 258-486 order
 Evidence X-RAY 5q0s C Reference
       Region 5q0s C 258-486 order
 Evidence X-RAY 5q0t A Reference
       Region 5q0t A 258-465 order
       Region 5q0t A 466-472 disorder
       Region 5q0t A 473-485 order
       Region 5q0t A 486-486 disorder
 Evidence X-RAY 5q0u A Reference
       Region 5q0u A 258-486 order
 Evidence X-RAY 5q0u C Reference
       Region 5q0u C 258-486 order
 Evidence X-RAY 5q0v A Reference
       Region 5q0v A 258-486 order
 Evidence X-RAY 5q0v C Reference
       Region 5q0v C 258-486 order
 Evidence X-RAY 5q0w A Reference
       Region 5q0w A 258-484 order
       Region 5q0w A 485-486 disorder
 Evidence X-RAY 5q0x A Reference
       Region 5q0x A 258-352 order
       Region 5q0x A 353-357 disorder
       Region 5q0x A 358-470 order
       Region 5q0x A 471-472 disorder
       Region 5q0x A 473-485 order
       Region 5q0x A 486-486 disorder
 Evidence X-RAY 5q0y A Reference
       Region 5q0y A 258-486 order
 Evidence X-RAY 5q0y C Reference
       Region 5q0y C 258-486 order
 Evidence X-RAY 5q0z A Reference
       Region 5q0z A 258-486 order
 Evidence X-RAY 5q0z C Reference
       Region 5q0z C 258-486 order
 Evidence X-RAY 5q10 A Reference
       Region 5q10 A 258-483 order
       Region 5q10 A 484-486 disorder
 Evidence X-RAY 5q11 A Reference
       Region 5q11 A 258-438 order
       Region 5q11 A 439-439 disorder
       Region 5q11 A 440-467 order
       Region 5q11 A 468-472 disorder
       Region 5q11 A 473-483 order
       Region 5q11 A 484-486 disorder
 Evidence X-RAY 5q12 A Reference
       Region 5q12 A 258-484 order
       Region 5q12 A 485-486 disorder
 Evidence X-RAY 5q13 A Reference
       Region 5q13 A 258-486 order
 Evidence X-RAY 5q13 C Reference
       Region 5q13 C 258-486 order
 Evidence X-RAY 5q14 A Reference
       Region 5q14 A 258-486 order
 Evidence X-RAY 5q14 C Reference
       Region 5q14 C 258-486 order
 Evidence X-RAY 5q15 A Reference
       Region 5q15 A 258-486 order
 Evidence X-RAY 5q15 C Reference
       Region 5q15 C 258-486 order
 Evidence X-RAY 5q16 A Reference
       Region 5q16 A 258-486 order
 Evidence X-RAY 5q16 C Reference
       Region 5q16 C 258-486 order
 Evidence X-RAY 5q18 A Reference
       Region 5q18 A 258-486 order
 Evidence X-RAY 5q18 C Reference
       Region 5q18 C 258-486 order
 Evidence X-RAY 5q19 A Reference
       Region 5q19 A 258-486 order
 Evidence X-RAY 5q19 C Reference
       Region 5q19 C 258-486 order
 Evidence X-RAY 5q1a A Reference
       Region 5q1a A 258-486 order
 Evidence X-RAY 5q1a C Reference
       Region 5q1a C 258-485 order
       Region 5q1a C 486-486 disorder
 Evidence X-RAY 5q1b A Reference
       Region 5q1b A 258-486 order
 Evidence X-RAY 5q1b C Reference
       Region 5q1b C 258-486 order
 Evidence X-RAY 5q1c A Reference
       Region 5q1c A 258-486 order
 Evidence X-RAY 5q1c C Reference
       Region 5q1c C 258-485 order
       Region 5q1c C 486-486 disorder
 Evidence X-RAY 5q1d A Reference
       Region 5q1d A 258-486 order
 Evidence X-RAY 5q1d C Reference
       Region 5q1d C 258-486 order
 Evidence X-RAY 5q1e A Reference
       Region 5q1e A 258-469 order
       Region 5q1e A 470-473 disorder
       Region 5q1e A 474-484 order
       Region 5q1e A 485-486 disorder
 Evidence X-RAY 5q1f A Reference
       Region 5q1f A 258-485 order
       Region 5q1f A 486-486 disorder
 Evidence X-RAY 5q1f C Reference
       Region 5q1f C 258-486 order
 Evidence X-RAY 5q1g A Reference
       Region 5q1g A 258-276 order
       Region 5q1g A 277-281 disorder
       Region 5q1g A 282-485 order
       Region 5q1g A 486-486 disorder
 Evidence X-RAY 5q1h A Reference
       Region 5q1h A 258-485 order
       Region 5q1h A 486-486 disorder
 Evidence X-RAY 5q1h C Reference
       Region 5q1h C 258-484 order
       Region 5q1h C 485-486 disorder
 Evidence X-RAY 5q1h E Reference
       Region 5q1h E 258-486 order
 Evidence X-RAY 5q1h G Reference
       Region 5q1h G 258-485 order
       Region 5q1h G 486-486 disorder
 Evidence X-RAY 5q1i A Reference
       Region 5q1i A 258-356 order
       Region 5q1i A 357-357 disorder
       Region 5q1i A 358-484 order
       Region 5q1i A 485-486 disorder
Seq 258-468 Hetero tetramer : IID00189Complex
 Evidence X-RAY 4wvd A Reference
       Region 4wvd A 258-290 order
       Region 4wvd A 291-291 disorder
       Region 4wvd A 292-468 order
 Evidence X-RAY 4wvd B Reference
       Region 4wvd B 258-258 disorder
       Region 4wvd B 259-369 order
       Region 4wvd B 370-371 disorder
       Region 4wvd B 372-468 order
Seq 258-483 Homo dimer :
 Evidence X-RAY 4oiv A Reference
       Region 4oiv A 258-276 order
       Region 4oiv A 277-292 disorder
       Region 4oiv A 293-483 order
 Evidence X-RAY 4oiv B Reference
       Region 4oiv B 258-351 order
       Region 4oiv B 352-358 disorder
       Region 4oiv B 359-474 order
       Region 4oiv B 475-475 disorder
       Region 4oiv B 476-483 order
Seq 258-486 Hetero dimer : IID00082Complex
 Evidence X-RAY 4qe6 A Reference
       Region 4qe6 A 258-352 order
       Region 4qe6 A 353-355 disorder
       Region 4qe6 A 356-486 order
 Evidence X-RAY 4qe8 A Reference
       Region 4qe8 A 258-354 order
       Region 4qe8 A 355-356 disorder
       Region 4qe8 A 357-469 order
       Region 4qe8 A 470-473 disorder
       Region 4qe8 A 474-486 order
 Evidence X-RAY 4qe8 B Reference
       Region 4qe8 B 258-354 order
       Region 4qe8 B 355-356 disorder
       Region 4qe8 B 357-468 order
       Region 4qe8 B 469-473 disorder
       Region 4qe8 B 474-486 order
 Evidence X-RAY 5iaw A Reference
       Region 5iaw A 259-486 order
 Evidence X-RAY 5iaw B Reference
       Region 5iaw B 259-485 order
       Region 5iaw B 486-486 disorder
 Evidence X-RAY 5ick A Reference
       Region 5ick A 258-486 order
 Evidence X-RAY 5ick B Reference
       Region 5ick B 258-486 order
 Evidence X-RAY 5q17 A Reference
       Region 5q17 A 258-467 order
       Region 5q17 A 468-472 disorder
       Region 5q17 A 473-484 order
       Region 5q17 A 485-486 disorder
 Evidence X-RAY 5wzx A Reference
       Region 5wzx A 258-286 order
       Region 5wzx A 287-298 disorder
       Region 5wzx A 299-355 order
       Region 5wzx A 356-361 disorder
       Region 5wzx A 362-485 order
 Evidence X-RAY 5wzx B Reference
       Region 5wzx B 258-286 order
       Region 5wzx B 287-296 disorder
       Region 5wzx B 297-355 order
       Region 5wzx B 356-361 disorder
       Region 5wzx B 362-485 order
Seq 258-486 Monomer :
 Evidence X-RAY 1osh A Reference
       Region 1osh A 258-280 order
       Region 1osh A 281-295 disorder
       Region 1osh A 296-485 order
       Region 1osh A 486-486 disorder
 Evidence X-RAY 3fli A Reference
       Region 3fli A 258-467 order
       Region 3fli A 468-474 disorder
       Region 3fli A 475-485 order
       Region 3fli A 486-486 disorder
 Evidence X-RAY 3l1b A Reference
       Region 3l1b A 258-277 order
       Region 3l1b A 278-292 disorder
       Region 3l1b A 293-485 order
       Region 3l1b A 486-486 disorder
Seq 258-486 Hetero dimer : IID00103Complex
 Evidence X-RAY 5q0i A Reference
       Region 5q0i A 258-471 order
       Region 5q0i A 472-473 disorder
       Region 5q0i A 474-485 order
       Region 5q0i A 486-486 disorder
Seq 260-486 Hetero dimer :
 Evidence X-RAY 3gd2 A Reference
       Region 3gd2 A 260-291 order
       Region 3gd2 A 292-292 disorder
       Region 3gd2 A 293-352 order
       Region 3gd2 A 353-353 disorder
       Region 3gd2 A 354-486 order
Seqphosphorylation
    145-145 Phosphoserine; by PKC/PRKCA
    164-164 Phosphoserine; by PKC/PRKCA
    456-456 Phosphothreonine; by PKC/PRKCZ
Seqacetylation
    167-167 N6-acetyllysine; by EP300
    227-227 N6-acetyllysine; by EP300
 
Prediction
NeProc
Disorder 1-132,218-295
Order 133-217,296-486
ProS 1-11,34-61,78-84,89-98,218-218,256-286
AlphaFold
Disorder 1-134,205-256,279-289,353-356,470-470,486-486
Order 135-204,257-278,290-352,357-469,471-485
Pfam Hmmer
PF00105 135-210 4.9e-43
PF00104 306-482 8.3e-48
Function
Function in SwissProt
Ligand-activated transcription factor. Receptor for bile acids (BAs) such as chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and allocholic acid (ACA). Plays a essential role in BA homeostasis through the regulation of genes involved in BA synthesis, conjugation and enterohepatic circulation. Also regulates lipid and glucose homeostasis and is involved innate immune response (PubMed:10334992, PubMed:10334993, PubMed:21383957, PubMed:22820415). The FXR-RXR heterodimer binds predominantly to farnesoid X receptor response elements (FXREs) containing two inverted repeats of the consensus sequence 5'-AGGTCA-3' in which the monomers are spaced by 1 nucleotide (IR-1) but also to tandem repeat DR1 sites with lower affinity, and can be activated by either FXR or RXR-specific ligands. It is proposed that monomeric nuclear receptors such as NR5A2/LRH-1 bound to coregulatory nuclear responsive element (NRE) halfsites located in close proximity to FXREs modulate transcriptional activity (By similarity). In the liver activates transcription of the corepressor NR0B2 thereby indirectly inhibiting CYP7A1 and CYP8B1 (involved in BA synthesis) implicating at least in part histone demethylase KDM1A resulting in epigenomic repression, and SLC10A1/NTCP (involved in hepatic uptake of conjugated BAs). Activates transcription of the repressor MAFG (involved in regulation of BA synthesis) (By similarity). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine) (PubMed:12754200, PubMed:15471871, PubMed:17895379). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine) (PubMed:10514450, PubMed:15239098, PubMed:16269519). In the intestine activates FGF19 expression and secretion leading to hepatic CYP7A1 repression (PubMed:12815072, PubMed:19085950). The function also involves the coordinated induction of hepatic KLB/beta-klotho expression (By similarity). Regulates transcription of liver UGT2B4 and SULT2A1 involved in BA detoxification; binding to the UGT2B4 promoter seems to imply a monomeric transactivation independent of RXRA (PubMed:12806625, PubMed:16946559). Modulates lipid homeostasis by activating liver NR0B2/SHP-mediated repression of SREBF1 (involved in de novo lipogenesis), expression of PLTP (involved in HDL formation), SCARB1 (involved in HDL hepatic uptake), APOE, APOC1, APOC4, PPARA (involved in beta-oxidation of fatty acids), VLDLR and SDC1 (involved in the hepatic uptake of LDL and IDL remnants), and inhibiting expression of MTTP (involved in VLDL assembly (PubMed:12660231, PubMed:12554753, PubMed:15337761). Increases expression of APOC2 (promoting lipoprotein lipase activity implicated in triglyceride clearance) (PubMed:11579204). Transrepresses APOA1 involving a monomeric competition with NR2A1 for binding to a DR1 element (PubMed:11927623, PubMed:21804189). Also reduces triglyceride clearance by inhibiting expression of ANGPTL3 and APOC3 (both involved in inhibition of lipoprotein lipase) (PubMed:12891557). Involved in glucose homeostasis by modulating hepatic gluconeogenesis through activation of NR0B2/SHP-mediated repression of respective genes. Modulates glycogen synthesis (inducing phosphorylation of glycogen synthase kinase-3) (By similarity). Modulates glucose-stimulated insulin secretion and is involved in insulin resistance (PubMed:20447400). Involved in intestinal innate immunity. Plays a role in protecting the distal small intestine against bacterial overgrowth and preservation of the epithelial barrier (By similarity). Down-regulates inflammatory cytokine expression in several types of immune cells including macrophages and mononuclear cells (PubMed:21242261). Mediates trans-repression of TLR4-induced cytokine expression; the function seems to require its sumoylation and prevents N-CoR nuclear receptor corepressor clearance from target genes such as IL1B and NOS2 (PubMed:19864602). Involved in the TLR9-mediated protective mechanism in intestinal inflammation. Plays an anti-inflammatory role in liver inflammation; proposed to inhibit proinflammatory (but not antiapoptotic) NF-kappa-B signaling) (By similarity).
Isoform 1
Promotes transcriptional activation of target genes NR0B2/SHP (inducible by unconjugated CDCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; low activity for ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA); not inducible by taurine- and glycine-amidated CDCA.
Isoform 2
Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA), NR0B2/SHP (inducible by unconjugated CDCA DCA and ACA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; not inducible by taurine- and glycine-amidated CDCA.
Isoform 3
Promotes transcriptional activation of target genes NR0B2/SHP (inducible by unconjugated CDCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and IBAP; low activity for ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA); not inducible by taurine- and glycine-amidated CDCA.
Isoform 4
Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, ACA and DCA), NR0B2/SHP (inducible by unconjugated CDCA, ACA and DCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; most efficient isoform compared to isoforms 1 to 3; not inducible by taurine- and glycine-amidated CDCA.
Biological Process
See also
Diagram with PDB data
NCOA1/RARACrystal structure of RARalpha ligand binding domain in complex with an agonist ligand (Am580) and a coactivator fragment